Physician profile
William Fuller
NPI 1326440488
$5,034.45
in general payments reported to CMS, 2019-2025
30 companies · $745 in 2025
The $745 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,278 · 2022: $1,770 · 2023: $502 · 2024: $739 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $664.00 | 2021-2025 | Mitraclip, Viewmate |
| Amgen INC. | $434.62 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $407.93 | 2021-2025 | |
| Medtronic, INC. | $407.65 | 2021-2025 | Linq II, Micra |
| Janssen Pharmaceuticals, INC | $377.18 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $338.09 | 2022-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $279.40 | 2022-2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.20 | 2021-2025 | Jardiance |
| Pfizer INC. | $184.26 | 2021-2025 | |
| Abiomed | $178.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $163.19 | 2021-2025 | Farxiga |
| Cvrx, INC. | $155.35 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $150.65 | 2022-2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $143.86 | 2021-2022 | |
| Cardiovascular Systems INC. | $116.46 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $114.31 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $100.18 | 2021-2023 | Verquvo |
| Heartflow, INC. | $97.27 | 2022 | |
| Baxter Healthcare | $86.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.30 | 2021-2025 | |
| Lantheus Medical Imaging, INC. | $57.72 | 2024-2025 | |
| Boston Scientific Corporation | $57.44 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $44.00 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $37.32 | 2021-2022 | |
| Irhythm Technologies, INC. | $34.52 | 2024 | Zio Monitor, Zio Xt Patch |
| Ablative Solutions, INC. | $23.19 | 2021 | |
| Amarin Pharma, INC. | $22.32 | 2022 | |
| Novo Nordisk INC | $18.14 | 2024 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $17.91 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tela Bio, INC. | $17.84 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.